Bio-link Australia Pty. Ltd.

24th December 2015 – Bio-Link Engaged by Oncology Venture

Bio-Link has been engaged by Oncology Venture to partner its clinical stage precision oncology drug candidates,

  • Irofulven – a phase II/III cytotoxic drug candidate under development together with a companion diagnostic technology (Irofulven DRP®) to identify patients highly likely to respond to therapy. Oncology Venture will soon commence a focused phase II trial of irofulven in highly likely patient responders with castration-resistant prostate cancer.
  • APO010 – a phase II-ready, highly potent Fas / CD95 / Apo1 agonist which mimics cytotoxic T-lymphocyte signalling to induce cancer cell apoptosis together with an immuno-companion diagnostic technology (APO010 DRP®) to identify patients highly likely to respond to therapy. Oncology Venture will soon commence phase II clinical studies in highly likely patient responders in metastatic breast cancer and multiple myeloma.

To read more about these partnering opportunities, please click here.

Oncology Venture